Compared to control cells, ASPP2‐depleted HCC‐LM3 and Hep‐G2 cells displayed significantly higher resistance to 5‐FU and Oxaliplatin co‐treatment. This evidence concerns the gene TP53BP2 and hepatocellular carcinoma.